Autism can correct when metabolic imbalance of the mitrochondria is supported
See: urea, metformin, creatine, nitric oxide
---
Antipurinergic therapy for autism-An in-depth review
Robert K Naviaux
Mitochondrion
2018 Nov;43:1-15.
PMID: 29253638
Abstract
Are the symptoms of autism caused by a treatable metabolic syndrome that traces to the abnormal persistence of a normal, alternative functional state of mitochondria? A small clinical trial published in 2017 suggests this is possible. Based on a new unifying theory of pathogenesis for autism called the cell danger response (CDR) hypothesis, this study of 10 boys, ages 5-14years, showed that all 5 boys who received antipurinergic therapy (APT) with a single intravenous dose of suramin experienced improvements in all the core symptoms of autism that lasted for 5-8weeks. Language, social interaction, restricted interests, and repetitive movements all improved. Two children who were non-verbal spoke their first sentences. None of these improvements were observed in the placebo group. Larger and longer studies are needed to confirm this promising discovery. This review introduces the concept of M2 (anti-inflammatory) and M1 (pro-inflammatory) mitochondria that are polarized along a functional continuum according to cell stress. The pathophysiology of the CDR, the complementary functions of M1 and M2 mitochondria, relevant gene-environment interactions, and the metabolic underpinnings of behavior are discussed as foundation stones for understanding the improvements in ASD behaviors produced by antipurinergic therapy in this small clinical trial.
Keywords: Antipurinergic therapy; Cell danger response; Ecoalleles; Ecogenetics; Epigenetics; M1 mitochondria; M2 mitochondria; Metabolism; Nucleotides; Purinergic signaling; Suramin.
Copyright © 2017 The Author. Published by Elsevier B.V. All rights reserved.
Similar articles
Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy.
Naviaux JC, Schuchbauer MA, Li K, Wang L, Risbrough VB, Powell SB, Naviaux RK. Transl Psychiatry. 2014 Jun 17;4(6):e400. doi: 10.1038/tp.2014.33. PMID: 24937094 Free PMC article.
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model.
Naviaux RK, Zolkipli Z, Wang L, Nakayama T, Naviaux JC, Le TP, Schuchbauer MA, Rogac M, Tang Q, Dugan LL, Powell SB. PLoS One. 2013;8(3):e57380. doi: 10.1371/journal.pone.0057380. Epub 2013 Mar 13. PMID: 23516405 Free PMC article.
Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model.
Naviaux JC, Wang L, Li K, Bright AT, Alaynick WA, Williams KR, Powell SB, Naviaux RK. Mol Autism. 2015 Jan 13;6:1. doi: 10.1186/2040-2392-6-1. eCollection 2015. PMID: 25705365 Free PMC article.
[Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].
Leboyer M, Bouvard MP, Launay JM, Recasens C, Plumet MH, Waller-Perotte D, Tabuteau F, Bondoux D, Dugas M. Encephale. 1993 Mar-Apr;19(2):95-102. PMID: 8275903 Review. French.
[Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
Baghdadli A, Gonnier V, Aussilloux C. Encephale. 2002 May-Jun;28(3 Pt 1):248-54. PMID: 12091786 Review. French.